EUPATI (European Patients‘ Academy on Therapeutic Innovation) launched the EUPATI Toolbox today. Funded by the Innovative Medicines Initiative, EUPATI provides scientifically reliable, objective, comprehensive information to patients on medicines research and development. The Toolbox covers the A to Z of how medicines are developed. Check it out here!
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 46 entries.
Entries by mercuric
MErCuRIC partners attended a successful meeting in Dublin, Ireland on 15 Jan 2016. Progress made by the consortium in year 2 was discussed and work for year 3 was planned. Our first Phase I study is drawing to a close and plans for the next Phase I work are well underway. We have also advanced the […]
MErCuRIC has been featured as a case study in the 2014- 2015 Annual Report of the Experimental Cancer Medicine Centre (ECMC) Network in the UK.
We’ve just launched a new patient area on the project website – have a look!
We’ve created a new area on the project website for publications from our partners that are relevant to MErCuRIC – check it out!
EUPATI, the European Patients’ Academy on Therapeutic Innovation has published their Oct 2015 newsletter – learn more about the experience of students who have just completed the first Patient Xpert Training Course and why regulatory agencies think patient education and engagement are important.
In an IFOM interview, MErCuRIC researcher Prof. Alberto Bardelli of the Universita Degli Studi di Torino talks about why he studies colorectal cancer. He describes personalised medicine, targeted therapies and resistance to therapy, as well as monitoring therapy in real time with blood-based assays called liquid biopsies. You can watch the interview here.
Educational videos from Cancer Research for Personalized Medicine (CARPEM) are now available online in French (English subtitles). Pr. Julien Taieb, gastrointestinal oncologist at the Georges Pompidou European Hospital (APHP), describes how advances in personalized medicine modify its practices in the treatment of digestive cancers.
MErCuRIC will be presented at the American Society of Clinical Oncology (ASCO) 2015 meeting, 29 May – 02 June 2015, in Chicago. A poster entitled ‘MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients’ will be included in the Gastrointestinal (Colorectal) Cancer […]
The Centre for Cancer Research and Cell Biology at Queen’s University Belfast, in conjunction with the Ireland-Northern Ireland-National Cancer Institute Consortium, will host the All-Ireland Cancer Consortium (AICC) Conference 2015 at the Riddel Hall, Queen’s University Belfast, between 10th and 13th May 2015. The focus of the conference will be on ‘New Horizons for Cancer: Removing […]
- Reflections from EAPM 2017 where MErCuRIC PPI was HighlightedDecember 14, 2017 - 8:11 am
- EuropaColon Patients’ Survey on The Unmet Needs of Patients Living with Metastatic Colorectal CancerDecember 4, 2017 - 3:35 pm
- MErCuRIC team from the Università degli Studi di Torino publish in NatureNovember 30, 2017 - 8:54 am
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.